SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Reflow Medical, Inc. has announced the completion of enrollment in its Wing-ITinvestigational device exemption trial, a prospective, multicenter, nonrandomized study evaluating the ability of the Wingman catheter to cross chronic total occlusions (CTOs) in peripheral lesions after failed guidewire attempts.
Eighty-five patients with advanced peripheral artery disease enrolled in the Wing-IT trial were evaluated at 12 centers in the U.S., Germany, and Austria. John R. Laird, MD, of Adventist Heart and Vascular Institute, St. Helena, California, is the principal investigator for the study.
“We would like to express our gratitude to the participating patients, physician investigators, research staff and employees. Their efforts have made it possible for us to reach this major milestone,” said Dr. Laird.
The Wingman Crossing Catheter uses an extendable beveled tip that creates a channel to help penetrate, or cross, the occlusion. This enables further treatment of the lesion with therapeutic devices.
Isa Rizk, Chief Executive Officer of Reflow Medical, commented, “Our goal is to expand the physician’s ability to treat CTOs, which often develop in patients with advanced peripheral artery disease. Facilitating CTO crossings helps physicians avoid amputations or bypass surgery, which directly correlates to better long-term outcomes.”
About Reflow Medical, Inc.
Reflow Medical, Inc. is a private company focused on empowering physicians through the design and development of innovative and effective technologies for cardiovascular disease. Reflow is developing a family of products to treat cardiovascular disease.